세계의 마프로틸린 염산염 API 시장 보고서(2025년)
Maprotiline Hydrochloride API Global Market Report 2025
상품코드 : 1760601
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,487,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,376,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,266,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

마프로틸린 염산염 API(원료의약품) 시장 규모는 향후 몇 년 동안 강력한 성장세를 보이며 2029년까지 6.7%의 CAGR로 15억 8,000만 달러 규모에 이를 것으로 예상됩니다. 예측 기간 동안 예상되는 성장의 원동력은 중추신경계 질환에 대한 관심 증가, 만성 우울증에 대한 인식 증가, 온라인 의약품 서비스의 가용성 확대, 장기지속형 항우울제 수요 증가, 정신의료 인프라에 대한 투자 증가 등입니다. 이 기간 동안 예상되는 주요 동향으로는 약물 합성의 기술 혁신, 항우울제 전달 방법의 진보, 정신과 치료에서 맞춤형 의료의 발전, 신경약리학 연구 개발의 증가, 새로운 기술을 통한 제조 기술의 부상 등을 들 수 있습니다.

정신 질환의 유병률 증가는 마프로틸린 염산염 API 시장의 확대를 촉진할 것으로 예상됩니다. 사람의 감정, 사고, 행동 및 전반적인 정신건강에 영향을 미치는 정신건강 장애는 개인의 일상 업무 수행 능력에 점점 더 많은 영향을 미치고 있습니다. 이러한 장애의 증가는 장시간 노동과 높은 압박감 등 스트레스가 많고 빠르게 변화하는 라이프스타일에 기인합니다. 마프로틸린 염산염 API는 우울증, 불안장애, 기분장애의 증상을 관리하는 효과적인 치료제로서 도움이 될 수 있습니다. 예를 들어, 2023년 11월 NHS Digital은 17-19세 청소년의 정신장애 유병률이 2021년 17.4%에서 2022년 25.7%로 크게 증가했다고 보고했습니다. 이처럼 정신질환 유병률의 증가는 마프로틸린 염산염 API 시장의 성장에 기여하고 있습니다.

의료비 증가는 마프로틸린 염산염 API 시장의 성장을 촉진할 것으로 예상됩니다. 병원 서비스, 의약품, 건강 보험 등의 비용을 포함한 의료비는 증가 추세에 있으며, 그 주요 원인은 더 빈번하고 복잡한 의료를 필요로 하는 고령화입니다. 이러한 의료비 증가는 특히 우울증과 같은 증상에 대한 마프로틸린 염산염과 같은 의약품 치료에 대한 수요를 촉진하고 있습니다. 예를 들어, 2023년 12월 미국 메디케어-메디케이드 서비스 센터(CMS)는 미국의 의료비가 2022년 4.1% 증가한 4조 5,000억 달러에 달해 2021년 3.2% 증가율을 넘어섰다고 보고했습니다. 이처럼 우울증과 불안증의 유병률 증가는 마프로틸린 염산염 API 시장의 성장에 박차를 가하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 거시경제 시나리오 : 금리·인플레이션·지정학·무역 전쟁·관세·코로나와 회복이 시장에 미치는 영향을 포함한다

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계 시장 : 경쟁 벤치마킹·대시보드

제33장 주요 기업 인수합병(M&A)

제34장 최근의 시장 동향

제35장 시장 잠재력 높은 나라·부문과 전략

제36장 부록

ksm
영문 목차

영문목차

Maprotiline hydrochloride API is the active ingredient found in antidepressant medications, typically prescribed to treat depression and sometimes anxiety disorders. It works by inhibiting the reuptake of neurotransmitters such as serotonin and norepinephrine in the brain, which helps improve mood, reduce anxiety, and promote emotional stability, making it an effective option for individuals with mood disorders.

The primary forms of maprotiline hydrochloride API include powder, granules, and others. The powdered form of maprotiline hydrochloride is processed and supplied as a powder, which is used in various formulations such as tablets, capsules, injectables, and oral solutions. These products are distributed through channels such as direct sales, pharmacy chains, online pharmacies, and hospital pharmacies. Maprotiline hydrochloride API is used in treatments for antidepressant, anxiolytic, sleep disorders, and neuropathic pain management, serving a range of end users including pharmaceutical companies, research institutions, healthcare providers, and contract manufacturing organizations (CMOs).

The maprotiline hydrochloride API market research report is one of a series of new reports from The Business Research Company that provides maprotiline hydrochloride API market statistics, including maprotiline hydrochloride API industry global market size, regional shares, competitors with a maprotiline hydrochloride API market share, detailed maprotiline hydrochloride API market segments, market trends and opportunities, and any further data you may need to thrive in the maprotiline hydrochloride API industry. This maprotiline hydrochloride API market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The maprotiline hydrochloride API market size has grown strongly in recent years. It will grow from $1.14 billion in 2024 to $1.22 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth during the historical period can be attributed to the rising prevalence of depression and anxiety disorders, an increase in psychiatric prescriptions, a growing demand for generic antidepressants, greater access to mental health treatments, and a rising number of elderly patients with mood disorders.

The maprotiline hydrochloride API market size is expected to see strong growth in the next few years. It will grow to $1.58 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The anticipated growth during the forecast period is driven by a heightened focus on central nervous system disorders, growing awareness of chronic depression, the expanding availability of online pharmaceutical services, a rising demand for long-acting antidepressant formulations, and increased investments in mental healthcare infrastructure. Key trends expected during this period include technological innovations in drug synthesis, advancements in antidepressant delivery methods, progress in personalized medicine for psychiatric treatments, increased research and development in neuropharmacology, and the rise of new technological manufacturing techniques.

The growing prevalence of mental health disorders is expected to drive the expansion of the maprotiline hydrochloride API market. Mental health disorders, which impact a person's emotions, thoughts, behavior, and overall mental well-being, are increasingly affecting individuals' ability to perform daily tasks. The rise in these disorders can be attributed to stressful and fast-paced lifestyles, characterized by long work hours and high job pressure. Maprotiline hydrochloride API serves as an effective treatment for managing symptoms of depression, anxiety, and mood disorders. For example, in November 2023, NHS Digital reported that the prevalence of probable mental disorders in young people aged 17 to 19 years rose from 17.4% in 2021 to 25.7% in 2022, indicating a significant increase. As such, the rising prevalence of mental health disorders is contributing to the growth of the maprotiline hydrochloride API market.

Rising healthcare expenditures are expected to drive the growth of the maprotiline hydrochloride API market. Healthcare spending, which includes costs for hospital services, pharmaceuticals, and health insurance, is on the rise, largely due to an aging population that requires more frequent and complex medical care. This increase in healthcare spending is driving demand for pharmaceutical treatments, such as maprotiline hydrochloride, especially for conditions such as depression. For instance, in December 2023, the Centers for Medicare & Medicaid Services (CMS) reported that U.S. healthcare spending grew by 4.1% to reach $4.5 trillion in 2022, outpacing the 3.2% increase seen in 2021. Thus, the rising incidence of depression and anxiety is fueling the growth of the maprotiline hydrochloride API market.

The surge in depression and anxiety cases is expected to accelerate the growth of the maprotiline hydrochloride API market. Depression and anxiety, which involve chronic feelings of sadness, worry, and fear, are increasingly impacting individuals' ability to function daily. The increase in these conditions is often linked to greater social isolation, as modern lifestyles, remote work, and smaller social communities have reduced face-to-face interactions, leading to heightened feelings of loneliness and emotional distress. Maprotiline hydrochloride API acts as a tetracyclic antidepressant that helps balance neurotransmitters in the brain, such as norepinephrine, and is beneficial in treating these conditions. For instance, in May 2024, the American Psychiatric Association noted that 43% of adults reported feeling more anxious in 2024 than in the previous year, up from 37% in 2023 and 32% in 2022. Consequently, the increasing incidence of depression and anxiety is driving the growth of the maprotiline hydrochloride API market.

Major players in the maprotiline hydrochloride api market are Thermo Fisher Scientific Inc., Lupin Limited, Olon Societa per Azioni, Cayman Chemical Company, Koa Shoji Co. Ltd., Simson Pharma Limited, Zydus Cadila, Conscientia Industrial Co. Ltd., Alsachim Societe par Actions Simplifiee, Pharmaoffer B.V., SynZeal Research Private Limited, Jigs Chemical, Chem-Impex International Inc., Pharma Compass, Allmpus Corporation, Glentham Life Sciences Limited, LKT Laboratories Inc., Qingdao Fengchen Technology and Trade Co. Ltd., Beijing Merson Pharmaceutical, Enomark Pharma

North America was the largest region in the maprotiline hydrochloride API market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in maprotiline hydrochloride API report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the maprotiline hydrochloride API market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The maprotiline hydrochloride API market consists of sales of products including extended-release tablets, oral solutions, syrups, topical preparations, and combination formulations. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Maprotiline Hydrochloride API Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on maprotiline hydrochloride api market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for maprotiline hydrochloride api ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The maprotiline hydrochloride api market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Maprotiline Hydrochloride API Market Characteristics

3. Maprotiline Hydrochloride API Market Trends And Strategies

4. Maprotiline Hydrochloride API Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Maprotiline Hydrochloride API Growth Analysis And Strategic Analysis Framework

6. Maprotiline Hydrochloride API Market Segmentation

7. Maprotiline Hydrochloride API Market Regional And Country Analysis

8. Asia-Pacific Maprotiline Hydrochloride API Market

9. China Maprotiline Hydrochloride API Market

10. India Maprotiline Hydrochloride API Market

11. Japan Maprotiline Hydrochloride API Market

12. Australia Maprotiline Hydrochloride API Market

13. Indonesia Maprotiline Hydrochloride API Market

14. South Korea Maprotiline Hydrochloride API Market

15. Western Europe Maprotiline Hydrochloride API Market

16. UK Maprotiline Hydrochloride API Market

17. Germany Maprotiline Hydrochloride API Market

18. France Maprotiline Hydrochloride API Market

19. Italy Maprotiline Hydrochloride API Market

20. Spain Maprotiline Hydrochloride API Market

21. Eastern Europe Maprotiline Hydrochloride API Market

22. Russia Maprotiline Hydrochloride API Market

23. North America Maprotiline Hydrochloride API Market

24. USA Maprotiline Hydrochloride API Market

25. Canada Maprotiline Hydrochloride API Market

26. South America Maprotiline Hydrochloride API Market

27. Brazil Maprotiline Hydrochloride API Market

28. Middle East Maprotiline Hydrochloride API Market

29. Africa Maprotiline Hydrochloride API Market

30. Maprotiline Hydrochloride API Market Competitive Landscape And Company Profiles

31. Maprotiline Hydrochloride API Market Other Major And Innovative Companies

32. Global Maprotiline Hydrochloride API Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Maprotiline Hydrochloride API Market

34. Recent Developments In The Maprotiline Hydrochloride API Market

35. Maprotiline Hydrochloride API Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기